Nordicus Partners Corp (NORD)

[e-ore]

Their patent doesn't show on the balance sheet but it's effective, as proven by the lack of infections with the Powerwand. Here's an excerpt from a study where the Powerwand was used instead of a standard PICC.

"Contrast these outcomes with the predictable consequences our patients would have had if PICCs had been mandated for all vancomycin administrations. At the low end of the reported PICC-associated bloodstream infection rate, approximately 16 patients in our cohort would have had catheter-associated bloodstream infections, and 1 or 2 of these patients quite possibly would have died. The unreimbursable cost of treating 16 patients with CLABSI would have been $896,000.23 Compare this with the actual hard-cost savings of $97,740 (1086 patients × $90 savings per procedure) that resulted from using the study midline catheter (the Powerwand) instead of a PICC for vancomycin administration."
http://www.avajournal.com/article/S1552-8855(16)30127-1/fulltext

Proof that what they have patented saves lives and money. If the Powerwand comes into common usage more eyes will be on it's effectiveness in preventing hospital acquired infections, and it is not only applicable to catheters. The possibility of a buyout would certainly bring in more buyers/investors. But, short term anyway, ASNB's profitablity and success depends on Powerwand sales.

"The Company believes that infection rates from MRSA, primarily from hospitals and other medical facilities, pose significant risks to patient populations and are increasing in frequency. In fact, the Centers for Disease Control and Prevention estimates that 250,000 catheter-related bloodstream infections cost the U.S. healthcare system about $4.6 billion a year."

"March 14, 2017
New Study Pushes POWERWAND Midline IV Catheter
to Over 20,000 Catheter Days with Zero BSIs"
http://3g033q44pk4o4eo9td3bwjsx.wpengine.netdna-cdn.com/wp-content/uploads/20000-Catheter-Days.pdf

Here's their patent
http://www.businesswire.com/news/home/20100825005505/en/AdvanSource-Biomaterials-Announces-Patent-Antimicrobial-Polyurethane-Resins